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Background: New onset diabetes mellitus (NODM) and acute rejection (AR) are important causes of morbidity and
risk factors for allograft failure after kidney transplantation.
Methods: In this multi-center, open label, single-arm pilot study, 49 adult (≥18 years of age), low immunologic risk,
non-diabetic recipients of a first deceased or living donor kidney transplant received early steroid reduction to
5 mg/day combined with ThymoglobulinW (Genzyme Transplant, Cambridge, MA, USA) induction, low dose
cyclosporine (2-hour post-dose (C2) target of 600 to 800 ng/ml) and mycophenolic acid (MPA) therapy.
Results: Six months after transplantation, two patients (4%) developed NODM and one patient (2%) developed AR.
Four patients had impaired fasting glucose tolerance based on 75-g oral glucose tolerance testing (OGTT). There
was one patient death. There were no episodes of cytomegalovirus (CMV) infection or BK virus nephritis. In contrast,
in a historical cohort of n = 27 patients treated with Thymoglobulin induction, and conventional doses of
cyclosporine and corticosteroids, the incidence of NODM and AR was 18% and 15%.
Conclusions: The pilot study results suggest that Thymoglobulin induction combined with early steroid reduction,
reduced cyclosporine exposure and MPA, may reduce the incidence of both NODM and AR in low immunological
risk patients. A future controlled study enriched for patients at high risk for NODM is under consideration.
Trial registration: ClinicalTrials.gov: NCT00706680
Keywords: New onset diabetes mellitus, Steroid minimization, Cyclosporine minimizationBackground
Despite a high level of awareness of steroid-related side
effects, the use of steroid elimination protocols remains
limited. A recent registry analysis of data accumulated by
the Scientific Registry for Transplant Recipients indicates
that only 35% of kidney transplant recipients are now
discharged home from hospital without corticosteroids
[1]. While short-term results of renal transplantation are
excellent, a recent evaluation of longer-term outcomes
has shown minimal if any improvement after the first year* Correspondence: edward.cole@uhn.ca
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reproduction in any medium, provided the orin the current era [2]. Therefore newer strategies to im-
prove long-term outcomes are required.
New onset diabetes mellitus (NODM) and acute rejec-
tion (AR) are important causes of morbidity and risk
factors for allograft failure by 5 years [3]. Accordingly,
strategies to reduce NODM while maintaining low rates
of AR would have the potential to improve long-term
outcomes. Recent studies have shown that early steroid
withdrawal had limited impact on NODM, but was
associated with a higher incidence of AR [4,5]. It is known
that NODM is associated with age, ethnicity, hepatitis C,
obesity, family history of diabetes and steroids as well as
calcineurin inhibitors, especially tacrolimus [6]. Accord-
ingly, it is possible that early steroid withdrawal was not asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hoped, in part, because of relatively high calcineurin in-
hibitor doses in one study and the use of tacrolimus in the
other [7]. Furthermore, there is also evidence that glucose
tolerance is not significantly different among patients
treated with low dose prednisone (5 mg/day) and those
treated with complete steroid withdrawal [8]. Therefore
complete withdrawal (with the potential for more AR)
might not be necessary. The main barriers to wider ac-
ceptance of steroid elimination are a higher incidence of
AR, the absence of clinically relevant improvements in
metabolic parameters and hypertension, and concerns
about long-term safety.
This pilot study was designed to address the first two
concerns. The risk of AR was addressed by the use of
ThymoglobulinW induction, and was informed by the
findings from the study of Woodle et al. [5] where the
overall higher rate of AR in the patients withdrawn from
corticosteroids compared to those who continued pred-
nisone in doses of 5 mg/day was driven by more AR in
the first 3 months after transplantation, but a similar
incidence of AR thereafter. We hypothesized that the
failure of the study of Woodle et al.[5] to demonstrate a
clinically relevant improvement in metabolic parameters,
such as NODM and kidney function with corticosteroid
withdrawal, was due to use of tacrolimus rather than
cyclosporine microemulsion, and relatively high tacrolimus
target levels after transplantation. Accordingly, we chose
to use cyclosporine microemulsion with a lower target
based on 2-hour post-dose (C2) monitoring.
This pilot, single-arm study was designed to deter-
mine the incidence of NODM and AR with the use of
Thymoglobulin, rapid reduction to prednisone 5 mg/day,
low-dose cyclosporine and mycophenolic acid (MPA) in
low risk patients. By comparing these results with those
from a historical cohort of patients, the pilot study would
provide information necessary to plan a definitive con-
trolled trial.Methods
Prospective pilot study
Study design and sample size
This was an open label, multi-center single-arm pilot
study performed in three Canadian transplant centers
(Toronto General Hospital, Toronto, St Michael’s Hospital,
Toronto, and St Paul’s Hospital, Vancouver) between
June 2008 and May 2010. A sample size of 50 patients
was planned to provide each center with adequate ex-
perience using the immunosuppressive regimen and
feasibility including available resources to perform
rigorous pre- and post-transplant testing for NODM.
The study was approved by the Hospital Research Ethics
Board in all three participating hospitals.Study population
Adult recipients (≥18 years of age) of a first deceased
or living donor kidney only transplant were eligible for
the study. Only non-diabetic patients were eligible: all
patients were required to have a normal 2-hour 75-g
oral glucose tolerance test (OGTT) (<7.8 mmol/l)
performed within 1 month of the date of transplantation.
Patients with an OGTT of 7.8 to 11.0 mmol/l were clas-
sified as having impaired glucose tolerance and were
included in the study, while patients with an OGTT
>11.0 mmol/l were excluded. In addition, patients were
excluded if they had pre-transplant Panel Reactive Anti-
body >20%, or if they received a zero A, B, DR mis-
matched kidney. Patients were also excluded if they were
unable to provide informed consent or were hepatitis C
antibody positive.Intervention
The immunosuppressive regimen consisted of Thymog-
lobulin induction (given pre-operatively or in the early
post-operative period, at a dose of 1 to 1.5 mg/kg/day,
total dose 4.5 to 7 mg/kg), Neoral cyclosporine (Novartis,
Basel, Switzerland)with a target C2 of 600 to 800 ng/ml
starting immediately after transplantation, and rapid
steroid reduction. All patients received methylpred-
nisolone 250 to 500 mg IV within 1 hour of transplan-
tation followed by prednisone orally at 1 mg/kg/day for
2 days, 0.5 mg/kg/day for 2 days, 0.25 mg/kg/day for 2 days
and then 5 mg/day. MPA was administered daily as
mycophenolate mofetil (MMF; CellCept, Roche, South
San Francisco, CA, USA) 2 g/day, or enteric-coated
mycophenolate sodium (EC-MPS; myfortic, Novartis)
1440 mg/day with adjustment as necessary for leucopenia
or gastrointestinal symptoms. All patients received
prophylaxis against cytomegalovirus (CMV) and Pneumo-
cystis cainii, according to center practice. AR was treated
per center practice with methylprednisolone IV as first
line therapy.Outcome
All outcomes were assessed at 6 months. The primary
outcome was NODM, which was defined using the
following sequential procedure: 1) the continuous use of
insulin or oral hypoglycemic medication during follow-up,
2) persistent hyperglycemia defined if >90% of all fasting
serum glucose values recorded during routine post-
transplant laboratory monitoring in the first 6 months
after transplantation were ≥7.0 mmol/l. If neither criteria
were met, a 75-gOGTT was performed 6 months after
transplantation. Patients with a 2-hour level >11.0 mmol/l
were considered diabetic, while patients with an OGTT
7.8 to 11.0 mmol/l were considered to have impaired
glucose tolerance.
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determined by biopsy based on Banff 97 criteria, or in
circumstances where a biopsy could not be readily
obtained, by clinical diagnosis. Other secondary outcomes
include patient and allograft survival. Safety outcomes
included infections (CMV infection or BK virus nephritis).
In addition, reactions to Thymoglobulin infusion (for
example hypotension) were documented.Historical cohort study
The outcomes of NODM and AR were assessed in a his-
torical cohort of n = 27 non-diabetic patients transplanted
at the Toronto General Hospital between January 2000
and December 2007. All patients included in the historical
cohort were adult (≥18 years of age) recipients of a first
deceased or living donor kidney only transplant, who
received Thymoglobulin induction followed by mainte-
nance immunosuppression with standard dose cyclospor-
ine (target C2 level of 1300 to 1500 ng/ml between month
0 to 3 post-transplant, followed by 800 to 1000 ng/ml in
months 3 to 6 post-transplant), MPA (the equivalent of
MMF 2 g/day), and prednisone (1 mg/kg/day for 3 days,
0.5 mg/kg/day for 4 days, 0.25 mg/kg/day to 1 month,
0.2 mg/kg/day to 2 months and then gradual reduction
to 5 mg/day). Patients included in the historical control
group were included in the electronic database maintained
by the Toronto General Hospital program, which includes
information on all prescribed medications and laboratory
test results performed for clinical indications before and
after transplantation. Patients in the historical control
group could not be subjected to the same protocol for
diagnosis of diabetes as patients enrolled in the prospect-
ive pilot study. Patients were excluded from the historical
control group if they had diabetes recorded as a cause of
renal failure, were prescribed insulin or oral hypoglycemic
medications prior to transplantation, or if they had >1
fasting serum glucose level greater than 7.0 mmol/l within
6 months prior to the date of transplantation. NODM was
determined 6 months after transplantation in the histor-
ical cohort by insulin or hypoglycemic medication use, or
if ≥90% of all fasting glucoses tests were ≥7.0 mmol/l. In
addition, patients in the historical cohort were classified
as having impaired glucose tolerance if ≥90% of fasting
plasma glucose tests were 5.6 to 6.9 mmol/l.Analytical methods
Continuous variables were described using the mean and
standard deviation (SD), while categorical variables were
described using proportions. Outcomes at 6 months after
transplantation, including NODM, AR, patient deaths,
death-censored transplant failures (including return to dia-
lysis or preemptive repeat transplantation), were described
using frequencies.Results and discussion
Prospective pilot study results
Characteristics of the patients enrolled in the prospect-
ive pilot study are shown in Table 1. Among the 49
patients enrolled in the pilot study, 96% received living
donor allografts, 62% were male, 69% were Caucasian,
and there were no African American patients. Prior to
transplantation, 38 of 49 patients (78%) were euglycemic
by OGTT and 11 patients (22%) had impaired glucose
tolerance. Thirty percent had BMI >30 and 82% of patients
were unsensitized whereas 18% had a panel reactive anti-
body (PRA) of 1 to 20%. No patient had a donor-specific
antibody at the time of transplantation.Protocol adherence
1 of 49 patients was switched from cyclosporine to
tacrolimus 1 day post-transplantation. That patient is
included in this intent to treat 6-month analysis.Primary outcome
NODM
One patient died shortly after transplantation and
excluded from these analyses. Two of forty-eight patients
(4%) developed NODM. Both patients had impaired glu-
cose tolerance prior to transplantation based on 2-hour
75-g OGTT. Four patients (8%) had impaired OGTT at
6 months after transplantation, including two patients
(50%) who had impaired glucose tolerance pre-transplant.
Forty-two patients (88%) were free of NODM and had
normal 2-hour 75-g OGTTs 6 months after transplant-
ation, including seven patients who had impaired glucose
tolerance prior to transplantation.
We examined the incidence of NODM in patents
at higher risk based on demographic characteristics.
Among the n= 11 patients >60 years of age included in
the study, 2/11 developed NODM, two had impaired
glucose tolerance after the 75-g OGTT and seven had
normal glucose levels after the OGTT. In comparison,
among the 37 patients ≤60 years of age, none developed
NODM, two patients had impaired glucose tolerance
after the 75-g OGTT and 35 had normal glucose levels
after OGTT. Among the 15 patients with pre-transplant
BMI >30, two developed NODM, one patient had impaired
glucose tolerance after 75-g OGTT and 12 had normal
glucose levels after OGTT. In comparison, among the
33 patients with BMI ≤30, 30 did not develop NODM and
three had impaired glucose tolerance. Looking at a com-
bination of age and BMI (Table 2), both patients who
developed NODM were >60 years of age and had a
BMI >30. Of the four patients with impaired glucose toler-
ance, two patients were >60 years of age and had BMI ≤30,
while two patients were ≤60 years of age, with one having
a BMI >30 and one having a BMI ≥30.
Table 1 Characteristics of patients enrolled in prospective
pilot study













Family history of diabetes 20%
BMI:







Zero PRA (%) 82%




1 to 2% 51%
3 to 6% 49%
Missing 0%











BMI, body mass index; ESRD, end stage renal disease; OGTT, oral glucose
tolerance test; PRA, panel reactive antibody; SD, standard deviation.




Age ≤60 years and BMI ≤30 (n = 27) 0 1 26
Age ≤60 years and BMI >30 (n = 10) 0 1 9
Age >60 years and BMI ≤30 (n = 6) 0 2 4
Age >60 years and BMI >30 (n = 5) 2 0 3
BMI, body mass index; OGTT, oral glucose tolerance test.
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AR: One of 48 patients (2%) had a clinically diagnosed
episode of AR at 16 days post-transplantation. Serum
creatinine in this patient was 149 uM at 6 months,
compared to 137 uM at the time of discharge post-
transplantation. The episode was treated with steroids
alone. This patient had a normal glucose level on the 75-g
OGTT test performed 6 months after transplantation.
Patient and allograft survival at 6 months: There was
one death 13 days post-transplantation due to severe
anoxic brain injury following sepsis. The remaining
48 patients were alive with functioning grafts at the end
of study. There were no episodes of CMV infection or
BK virus nephritis during follow-up and no infusion
reactions to Thymoglobulin were documented.
Blood pressure, kidney function and cholesterol: Mean
systolic and diastolic blood pressure (SD) was 135(21)/
82 (9) mmHg pre-transplant and 128(11)/78 mmHg at 6
months post-transplant. The mean number of blood
pressure medications (SD) was 1.35(1.27) pre-transplant
and 1.12(0.91) post-transplant.
At 6 months, the mean ±SD of the serum creatinine was
119 ±39 μM with Modification of Diet in Renal Disease
(MDRD) estimated GFR (SD) of 62 (10) ml/min/1.73m2.
Total fasting cholesterol at 6 months was <5.2 mmol/l in
51% and >5.2 mmol/l in 49%, with an LDL of <2.6 mmol/l
in 39% and ≥2.6 mmol/l in 61%. Twenty-seven (55%)
patients were not taking a lipid-lowering medication, while
14(30%) were taking one medication, and seven(15%) were
taking more than one lipid-lowering medication.Historical cohort results
There were a total of n = 27 patients included in the his-
torical cohort who received Thymoglobulin induction
and maintenance immunosuppression with conventional
doses of cyclosporine and prednisone along with MPA.
The characteristics of the historical control group and
comparison with the prospective study patients are
shown in Table 3. Among historical controls, the inci-
dence of NODM was 5/27 (18%), while 4/27 (15%) had
impaired fasting glucose and 18/27 (67%) had normal
fasting glucose measurements. The incidence of AR was
4/27(15%) in this group (Table 3).





group n = 27
P value
Age (mean ±SD) 44 ±14 years 49 ±13 years P=0.14
Male 62% 85% P=0.03
Race/ethnicity:
Caucasian 69% 41% P=0.21





Polycystic disease 18% 11%
Other known cause 51% 41%
Unknown 6% 15% P=0.41
BMI:
Mean ±SD 28 ±5 29 ±6 P=0.57






Living donor 96% 22% P<0.0001
Diabetes at 6 months:
Euglycemic 88% 67% P=0.07
Impaired 8% 15%
NODAT 4% 18%
AR at 6 months 2% 15% P=0.033
AR, acute rejection; BMI, body mass index; ESRD, end stage renal disease;
NODAT, new onset diabetes after transplantation; SD, standard deviation.
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The purpose of this prospective pilot study was to deter-
mine whether a strategy of early steroid reduction, but
not complete withdrawal, in association with low dose
cyclosporine, MPA and Thymoglobulin, would maintain
low rates of AR while minimizing the development of
NODM. In 48 patients followed for 6 months, there was
only one episode of AR, two new cases of NODM (both
with impaired glucose tolerance pre-transplant) and two
new cases of impaired glucose tolerance. These results
compare favorably to those in a historical cohort who in
particular had a higher incidence of NODM. We believe
that this protocol was successful in minimizing both im-
portant metabolic and immunologic complications of
transplantation over the short-term.
The benefits of early steroid withdrawal are controver-
sial. In 2009, a large retrospective review of US data
showed no reduction in 4-year graft and patient survival
in patients discharged from hospital on a steroid-freeregimen [9]. Although, in fact graft and patient survival
were significantly better in steroid-free patients, the
authors comment that the difference was slight and can-
not be presumed to be related to steroids because of the
retrospective registry-based nature of the study. Another
similar retrospective review found that steroids are
initiated in a significant percentage of patients initially
discharged without them and that this group has lower
graft survival than those discharged on steroids [10]. A
recent study from the Minneapolis group showed
reduced NODM (based on treatment alone), avascular
necrosis, cataracts and CMV infection compared to a
retrospective control group. However, it should be noted
that much higher steroid doses were used in that group
compared with practice today, that is 0.4 mg/kg at 1
month and down to 0.15 mg/kg/day at 1 year. Therefore,
it is by no means clear that early steroid withdrawal
would have these benefits versus the much lower steroid
doses used today in steroid-containing protocols. Accord-
ingly, the optimal long-term strategy remains unclear.
Other larger, randomized controlled trials have attempted
to maintain freedom from both AR and NODM. The
multicenter US study [5] was a randomized double-blind
controlled trial over 5 years. In that study, tacrolimus was
the calcineurin inhibitor used, steroids were withdrawn
completely and some patients received Thymoglobulin,
whereas others received anti-CD25 antibodies. Both
biopsy-proven AR and chronic allograft nephropathy were
more common in the steroid withdrawn group. However,
there was no overall difference in NODM based on blood
glucose testing although fewer subjects in the steroid with-
drawal group needed insulin. There were also no major
benefits shown in other cardiovascular risk factors. In the
Freedom study, there were 3 groups: standard steroids,
steroid withdrawal and a group receiving no steroids. Once
again steroid withdrawal (and steroid-free) protocols were
associated with significantly more AR. Reduced NODM
was only seen in the steroid-free group, which also had the
highest AR rate. Of note, two earlier studies did not dem-
onstrate a higher AR rate after steroid withdrawal, but in
both cases patients in the control group did not receive
induction, potentially accounting for a higher incidence
of rejection in those patients [11,12].
The most common causes of late graft loss are patient
death and combined interstitial fibrosis and tubular atro-
phy. Cardiovascular disease is the commonest cause of
patient death [13]. Several studies have shown that
NODM is associated with both patient death and death-
censored graft loss [2,14]. Recent work has demonstrated
that NODM occurs in up to 20% of patients in the first
year post-transplant [15,16]. It has been suggested, based
on retrospective data, which likely underestimates NODM
incidence, that NODM is associated with a 90% increase
in mortality and 60% increase in graft loss within 3 years
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an important goal with the potential to significantly im-
prove long-term graft loss.
Previous studies have shown that tacrolimus is associated
with a greater risk of NODM than cyclosporine A [14,17],
with similar AR rates when cyclosporine is monitored
by C2 [16]. Accordingly we chose cyclosporine as the
calcineurin inhibitor in this protocol to minimize NODM
risk and antibody induction, to reduce AR risk and permit
reduced cyclosporine exposure [4,18]. We chose Thymog-
lobulin induction based on US data showing a trend to-
wards less AR versus CD25 antibody induction in patients
in the early steroid withdrawal arm [5].
While steroid dose reduction would be expected to
improve glycemic control, a previous study has shown
no additional benefit in glucose control of complete
steroid withdrawal below 5 mg/day of prednisone [8].
Accordingly, in an effort to keep AR rates low, we chose
to reduce steroids rapidly but to maintain prednisone at
5 mg/day. Our very low incidence of NODM seems
superior to that seen by Vincenti et al. at 1 year [4],
using higher cyclosporine targets, of 14.7% in patients
on cyclosporine with standard steroids, or 12.2% in those
in whom steroids were withdrawn in 1 week. However,
that study included many Agfrican American Black
patients, known to be at higher risk of NODM.
The issue of the long-term safety of steroid-sparing
regimens is historically linked to the Canadian Multicentre
Transplant Study Group [19] because of a higher risk of
graft loss in those in whom steroids were discontinued.
However, that study had significant methodological prob-
lems and the immunosuppression protocols were signifi-
cantly less effective than those in current use. Despite
equivalent graft and patient survival at 5 years in the US
study, long-term safety concerns were renewed with
findings from a secondary analysis involving a sample of
patients with available biopsy data that showed a signifi-
cantly higher rate of chronic allograft nephropathy in the
corticosteroid withdrawal (CSWD) group [5] It was never
clarified whether this was attributable to patients with AR
in the CSWD group. A recent observational study from
the University of Minnesota reported excellent 10-year
outcomes with rapid steroid discontinuation and should
address the concerns regarding the long-term safety of
CSWD at least in Caucasian patients [11].
The major strength of our study is exclusion of diabetic
patients from the pilot study and rigorous assessment of
NODM after transplantation. The major limitation is a lack
of prospective control group and relatively few patients at
high risk for NODM based on demographic features.
Comparisons with the historical control group reinforce
our clinical impression that this regimen safely reduces
NODM and AR, and we have continued to use this regi-
men in clinical practice in low immunological risk patientswith high risk of NODM, based on historical features,
while we plan a definitive study enriched for patients
at greater risk for NODM than those included in this
pilot study.
Conclusions
In summary, a protocol consisting of Thymoglobulin,
early steroid reduction to 5 mg/dayof prednisone, low
dose cyclosporine dosed by C2 levels, and MPA as im-
munosuppression resulted in a low rate of both AR and
NODM. Thus, this protocol is worthy of further evalu-
ation as a means to preventing these important post-
transplant complications.
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